Table of Contents



UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 


FORM 10-Q


 

Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

for the quarterly period ended MarchSeptember 310,2019

or

 

Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

for the transition period from             to             

 

Commission File Number: 001-35020

 


INFUSYSTEM HOLDINGS, INC.

(Exact name of registrant as specified in its charter)


 

Delaware

20-3341405

(State or Other Jurisdiction of
Incorporation or Organization)

(I.R.S. Employer
Identification No.)

 

31700 Research Park Drive

Madison Heights, Michigan 48071

(Address of Principal Executive Offices) (Zip Code)

 

Registrant’s Telephone Number, including Area Code: (248) 291-1210


Securities Registered Pursuant to Section 12(b) of the Act:

Title of Each Class

Trading Symbol(s)

Name of Each Exchange on which Registered

Common Stock, par value $0.0001 per share

INFU

NYSE American LLC

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the pastpreceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days.    Yes  ☒    No    ☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).    Yes  ☒    No    ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer ☐ Accelerated filer ☐Non-accelerated filer ☒Smaller reporting company ☒
Emerging growth company ☐

      Large accelerated filer ☐        Accelerated filer ☐     Non-accelerated filer ☒     Smaller reporting company ☒

      Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Securities Exchange Act).    Yes  ☐    No   ☒

 

Securities Registered Pursuant to Section 12(b) of the Act:

Title of Each Class

Trading Symbol(s)

Name of Each Exchange on which Registered

Common Stock, par value $0.0001 per share

INFU

NYSE American LLC

As of May 10,November 8, 2019, 19,702,80719,843,021 shares of the registrant’s common stock, par value $0.0001 per share, were outstanding.

 



 

 

 

INFUSYSTEM HOLDINGS, INC. AND SUBSIDIARIES

 

Index to Form 10-Q

 

   

 

 

PAGE 

PART I -

FINANCIAL INFORMATION

 

   

Item 1.

Financial Statements

 3

   

 

-UnauditedUnaudited Condensed Consolidated Balance Sheets as of March 31,September 30, 2019 and December 31, 2018

 

 

-UnauditedUnaudited Condensed Consolidated Statements of Operations for the three and nine months ended March 31,September 30, 2019 and 2018

 

 

-UnauditedUnaudited Condensed Consolidated Statements of Stockholders’ Equity for the three and nine months ended March 31,September 30, 2019 and 2018

 

 

-UnauditedUnaudited Condensed Consolidated Statements of Cash Flows for the threenine months ended March 31,September 30, 2019 and 2018

 

 

-NotesNotes to the Unaudited Condensed Consolidated Financial Statements

 

   

Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

1416

   

Item 3.

Quantitative and Qualitative Disclosures About Market Risk

1721

   

Item 4.

Controls and Procedures

1721

   

PART II -

OTHER INFORMATION

 

   

Item 1.

Legal Proceedings

1821

   

Item 1A.

Risk Factors

1822

   

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

1822

   

Item 3.

Defaults Upon Senior Securities

1822

   

Item 4.

Mine Safety Disclosures

1822

   

Item 5.

Other Information

1822

   

Item 6.

Exhibits

1923

   

 

Signatures

2024

 

 

 

 

PART I – I—FINANCIAL INFORMATION

 

Item 1.

Financial Statements

 

 

INFUSYSTEM HOLDINGS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

(UNAUDITED)

 

 

As of

  

As of

 
 

March 31,

  

December 31,

  

September 30,

  

December 31,

 

(in thousands, except share data)

 

2019

  

2018

  

2019

  

2018

 
                

ASSETS

                

Current assets:

                

Cash and cash equivalents

 $1,900  $4,318  $3,157  $4,318 

Accounts receivable, net

  10,475   9,593   11,462   9,593 

Inventories

  2,553   2,254   2,768   2,254 

Other current assets

  1,470   1,372   1,605   1,372 
        

Total current assets

  16,398   17,537   18,992   17,537 

Medical equipment for sale or rental

  1,810   1,601   2,051   1,601 

Medical equipment in rental service, net of accumulated depreciation

  26,109   23,488   32,269   23,488 

Property & equipment, net of accumulated depreciation

  1,368   1,445   2,845   1,445 

Intangible assets, net

  18,740   19,865   16,539   19,865 

Operating lease right of use assets

  2,671   -   5,004   - 

Other assets

  149   137   195   137 
        

Total assets

 $67,245  $64,073  $77,895  $64,073 
                

LIABILITIES AND STOCKHOLDERS’ EQUITY

                

Current liabilities:

                

Accounts payable

 $9,672  $7,091  $10,669  $7,091 

Capital lease liability, current

  -   33 

Current portion of long-term debt

  5,337   4,903   7,009   4,903 

Other current liabilities

  3,466   2,763   4,136   2,796 
        

Total current liabilities

  18,475   14,790   21,814   14,790 

Long-term debt, net of current portion

  27,519   28,842   30,342   28,842 

Deferred income taxes

  29   -   76   - 

Operating lease liabilities, net of current portion

  1,479   -   3,944   - 
        

Total liabilities

  47,502   43,632   56,176   43,632 
                

Stockholders’ equity:

                

Preferred stock, $.0001 par value: authorized 1,000,000 shares; none issued

  -   -   -   - 

Common stock, $.0001 par value: authorized 200,000,000 shares; issued and outstanding 23,221,296 and 19,702,807, respectively, as of March 31, 2019 and 23,095,513 and 19,577,024, respectively, as of December 31, 2018

  2   2 

Common stock, $.0001 par value: authorized 200,000,000 shares; issued and outstanding 23,356,308 and 19,837,819, respectively, as of September 30, 2019 and 23,095,513 and 19,577,024, respectively, as of December 31, 2018

  2   2 

Additional paid-in capital

  83,429   83,167   83,889   83,167 
        

Retained deficit

  (63,688)  (62,728)  (62,172)  (62,728)
        

Total stockholders’ equity

  19,743   20,441   21,719   20,441 
        

Total liabilities and stockholders’ equity

 $67,245  $64,073  $77,895  $64,073 

 

See accompanying notes to unaudited condensed consolidated financial statements.

 

3

Table of Contents

 

INFUSYSTEM HOLDINGS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS 

(UNAUDITED)

 

  

Three Months Ended

 

(in thousands, except share and per share data)

 

March 31

 
  

2019

  

2018

 

Net revenues

  18,193   16,483 

Cost of revenues

  7,852   6,246 

Gross profit

  10,341   10,237 
         

Selling, general and administrative expenses:

        

Amortization of intangibles

  1,125   1,187 

Selling and marketing

  2,602   2,301 

General and administrative

  7,034   6,161 

Total selling, general and administrative

  10,761   9,649 
         

Operating (loss) income

  (420)  588 

Other expense:

        

Interest expense

  (460)  (315)

Other expense

  (21)  (11)
         

(Loss) income before income taxes

  (901)  262 

Provision for income taxes

  (59)  (58)

Net (loss) income

 $(960) $204 
         

Net (loss) income per share:

        

Basic

 $(0.05) $0.01 

Diluted

  (0.05)  0.01 

Weighted average shares outstanding:

        

Basic

  19,580,049   22,799,221 

Diluted

  19,580,049   22,857,121 

  

Three Months Ended

  

Nine Months Ended

 

(in thousands, except share and per share data)

 

September 30

  

September 30

 
  

2019

  

2018

  

2019

  

2018

 
                 

Net revenues

 $21,489  $16,677  $59,405  $49,575 

Cost of revenues

  9,251   7,003   25,470   19,978 

Gross profit

  12,238   9,674   33,935   29,597 
                 

Selling, general and administrative expenses:

                

Amortization of intangibles

  1,077   1,160   3,326   3,512 

Selling and marketing

  2,402   2,323   7,480   6,950 

General and administrative

  7,096   6,286   20,915   18,846 
                 

Total selling, general and administrative

  10,575   9,769   31,721   29,308 
                 

Operating income (loss)

  1,663   (95)  2,214   289 

Other expense:

                

Interest expense

  (488)  (370)  (1,436)  (981)

Other expense

  (11)  (9)  (71)  (19)
                 

Income (loss) before income taxes

  1,164   (474)  707   (711)

Provision for income taxes

  (29)  (45)  (151)  (109)

Net income (loss)

 $1,135  $(519) $556  $(820)
                 

Net income (loss) per share:

                

Basic

 $0.06  $(0.03) $0.03  $(0.04)

Diluted

  0.05   (0.03)  0.03   (0.04)

Weighted average shares outstanding:

                

Basic

  19,781,527   20,672,688   19,690,737   22,043,213 

Diluted

  20,679,431   20,672,688   20,503,933   22,043,213 

 

See accompanying notes to unaudited condensed consolidated financial statements.

 

-

4

Table of Contents

 

INFUSYSTEM HOLDINGS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF

STOCKHOLDERS’ EQUITY

(UNAUDITED)

 

 

Common Stock

  

Additional

      

Treasury Stock

  

Total

  

Common Stock

  

Additional

      

Treasury Stock

  

Total

 
     

Par Value

  

Paid in

  

Retained

      

Par Value

  

Stockholders’

      

Par Value

  

Paid in

  

Retained

      

Par Value

  

Stockholders’

 

(in thousands)

 

Shares

  

Amount

  

Capital

  

Deficit

  

Shares

  

Amount

  

Equity

  

Shares

  

Amount

  

Capital

  

Deficit

  

Shares

  

Amount

  

Equity

 

Balances at June 30, 2018

  23,032  $2  $91,587  $(61,934)  (578) $-  $29,655 

Stock based shares issued upon vesting - gross

  -   -   -   -   -   -   - 

Stock-based compensation expense

  -   -   453   -   -   -   453 

Employee stock purchase plan

  19   -   45   -   -   -   45 

Common stock repurchased as part of Repurchase Program

  -   -   (9,027)  -   (2,907)  -   (9,027)

Net loss

  -   -   -   (519)  -   -   (519)

Balances at September 30, 2018

  23,051  $2  $83,058  $(62,453)  (3,485) $-  $20,607 
                            

Balances at June 30, 2019

  23,237  $2  $83,557  $(63,307)  (3,518) $-  $20,252 

Stock based shares issued upon vesting - gross

  121   -   109   -   -   -   109 

Stock-based compensation expense

  -   -   240   -   -   -   240 

Employee stock purchase plan

  14   -   70   -   -   -   70 

Common stock repurchased to satisfy minimum statutory withholding on stock-based compensation

  (16)  -   (87)  -   -   -   (87)

Net income

  -   -   -   1,135   -   -   1,135 

Balances at September 30, 2019

  23,356  $2  $83,889  $(62,172)  (3,518) $-  $21,719 
                            

Balances at December 31, 2017

  22,978  $2  $92,584  $(61,633)  (198) $-  $30,953   22,978  $2  $92,584  $(61,633)  (198) $-  $30,953 

Stock based shares issued upon vesting - gross

  25   -   -   -   -   -   -   29   -   -   -   -   -   - 

Stock-based compensation expense

  -   -   112   -   -   -   112   -   -   679   -   -   -   679 

Employee stock purchase plan

  -   -   46   -   -   -   46   44       91               91 

Common stock repurchased to satisfy minimum statutory withholding on stock-based compensation

  -   -   (5)  -   -   -   (5)

Common stock repurchased as part of Repurchase Program

  -   -   (83)  -   (32)  -   (83)  -   -   (10,291)  -   (3,287)  -   (10,291)

Net income

  -   -   -   204   -   -   204 

Balances at March 31, 2018

  23,003  $2  $92,659  $(61,429)  (230) $-  $31,232 

Net loss

  -   -   -   (820)  -   -   (820)

Balances at September 30, 2018

  23,051  $2  $83,058  $(62,453)  (3,485) $-  $20,607 
                                                        

Balances at December 31, 2018

  23,096  $2  $83,167  $(62,728)  (3,518) $-  $20,441   23,096  $2  $83,167  $(62,728)  (3,518) $-  $20,441 

Stock based shares issued upon vesting - gross

  151   -   -   -   -   -   -   288   -   124   -   -   -   124 

Stock-based compensation expense

  -   -   246   -   -   -   246   -   -   770   -   -   -   770 

Employee stock purchase plan

  19       53               53   33       123               123 

Common stock repurchased to satisfy minimum statutory withholding on stock-based compensation

  (45)  -   (37)  -   -   -   (37)  (61)  -   (295)  -   -   -   (295)

Net loss

  -   -   -   (960)  -   -   (960)

Balances at March 31, 2019

  23,221  $2  $83,429  $(63,688)  (3,518) $-  $19,743 

Net income

  -   -   -   556   -   -   556 

Balances at September 30, 2019

  23,356  $2  $83,889  $(62,172)  (3,518) $-  $21,719 

 

See accompanying notes to unaudited condensed consolidated financial statementsstatements.

 

5

Table of Contents

 

INFUSYSTEM HOLDINGS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(UNAUDITED)

 

 

Three Months Ended

  

Nine Months Ended

 
 

March 31

  

September 30

 

(in thousands)

 

2019

  

2018

  

2019

  

2018

 

NET CASH PROVIDED BY OPERATING ACTIVITIES

 $1,269  $1,053  $9,534  $8,210 
                

INVESTING ACTIVITIES

                

Purchase of medical equipment and property

  (3,535)  (1,120)

Proceeds from sale of medical equipment and property

  764   955 

Purchase of medical equipment, property and equipment

  (16,420)  (4,521)

Proceeds from sale of medical equipment, property and equipment

  2,239   2,344 

NET CASH USED IN INVESTING ACTIVITIES

  (2,771)  (165)  (14,181)  (2,177)
                

FINANCING ACTIVITIES

                

Principal payments on term loans and capital lease obligations

  (929)  (2,790)

Principal payments on term loans, capital lease obligations and other financing

  (3,915)  (5,048)

Cash proceeds from term loans, equipment line and other financing

  7,462   9,660 

Debt issuance costs

  (3)  -   (3)  (27)

Common stock repurchased to satisfy statutory withholding on employee stock based compensation plans

  (37)  -   (295)  (5)

Common stock repurchased as part of Repurchase Program

  -   (83)  -   (10,291)

Cash proceeds - stock plans

  53   46 

NET CASH USED IN FINANCING ACTIVITIES

  (916)  (2,827)

Cash proceeds from stock plans

  237   91 

NET CASH PROVIDED BY (USED IN) FINANCING ACTIVITIES

  3,486   (5,620)
                

Net change in cash and cash equivalents

  (2,418)  (1,939)  (1,161)  413 

Cash and cash equivalents, beginning of period

  4,318   3,469   4,318   3,469 

Cash and cash equivalents, end of period

 $1,900  $1,530  $3,157  $3,882 

 

See accompanying notes to unaudited condensed consolidated financial statements.

 

6

Table of Contents

 

-960 

INFUSYSTEM HOLDINGS, INC. AND SUBSIDIARIES

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

 

 

1.

Basis of Presentation, Nature of Operations and Summary of Significant Accounting Policies

 

The terms “InfuSystem”, the “Company”, “we”, “our” and “us” are used herein to refer to InfuSystem Holdings, Inc. and its subsidiaries. InfuSystem is a leading provider of infusion pumps and related products and services. The Company provides products and services to hospitals, oncology practices and facilities and other alternative site healthcare providers. Headquartered in Madison Heights, Michigan, the Company delivers local, field-based customer support, and also operates pump repair Centers of Excellence in Michigan, Kansas, California, Massachusetts and Ontario, Canada.

 

The accompanying unaudited condensed consolidated financial statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) for interim financial information. Accordingly, the unaudited condensed consolidated financial statements do not include all of the information and notes required by U.S. Generally Accepted Accounting Principles (“GAAP”) for complete financial statements. The accompanying unaudited condensed consolidated financial statements include all adjustments, composed of normal recurring adjustments, considered necessary by management to fairly state the Company’s results of operations, financial position and cash flows. The operating results for the interim periods are not necessarily indicative of results that may be expected for any other interim period or for the full year. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2018 as filed with the SEC.

 

The unaudited condensed consolidated financial statements are prepared in conformity with GAAP, which requires the use of estimates, judgments and assumptions that affect the amounts of assets and liabilities at the reporting date and the amounts of revenue and expenses in the periods presented. The Company believes that the accounting estimates employed are appropriate and the resulting balances are reasonable; however, due to the inherent uncertainties in making estimates, actual results could differ from the original estimates, requiring adjustments to these balances in future periods.

 

Certain prior period reclassifications were made to conform with the current period presentation. These reclassifications had no effect on reported income (loss) income,, overall cash flows, total assets, total liabilities or stockholders’ equity as previously reported.

 

 

2.

2.Recent Accounting Pronouncements and Developments

Recent Accounting Pronouncements and Developments

 

In January 2017,June 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2017-04, “Intangibles - Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment”, which changes the subsequent measurement of goodwill impairment by eliminating Step 2 from the impairment test. Under the new guidance, an entity will measure impairment using the difference between the carrying amount and the fair value of the reporting unit. The new standard is effective for fiscal years beginning after December 15, 2019 (i.e. a January 1, 2020 effective date), with early adoption permitted for goodwill impairment tests with measurement dates after January 1, 2017. The Company believes the adoption will not have a material impact on its consolidated balance sheets, statements of operations, statements of cash flows and related disclosures.

In June 2016, the FASB issued ASU No. 2016-13, “Financial Instruments (Topic 326) Credit Losses”. Topic 326 changes the impairment model for most financial assets and certain other instruments. Under the new standard, entities holding financial assets and net investment in leases that are not accounted for at fair value through net income are to be presented at the net amount expected to be collected. An allowance for credit losses will be a valuation account that will be deducted from the amortized cost basis of the financial asset to present the net carrying value at the amount expected to be collected on the financial asset. Topic 326 is effective as of January 1, 2020. Early adoption is permitted. The Company is currently evaluating the impact of Topic 326 on its consolidated balance sheets, statements of operations, statements of cash flows and related disclosures.

 

 

3.

Revenue Recognition

 

The following table presents the Company’s disaggregated revenue by offering type:

 

  

Three Months Ended

 
  

March 31

 
  

2019

  

2018

 
       

Third-Party Payor Rentals

 48.1%  48.6% 

Direct Payor Rentals

 34.7%  38.9% 

Product Sales

 17.2%  12.5% 
       

Total - Net revenues

 100.0%  100.0% 
  

Three Months Ended

  

Nine Months Ended

 
  

September 30

  

September 30

 
  

2019

  

2018

  

2019

  

2018

 
                 

Third-Party Payor Rentals

  49.6%  46.8%  49.1%  47.6%

Direct Payor Rentals

  30.8%  35.8%  32.7%  37.6%

Product Sales

  19.6%  17.4%  18.2%  14.8%
                 

Total - Net revenues

  100.0%  100.0%  100.0%  100.0%

 

7

Table of Contents

 

4.4.

Medical Equipment

 

Medical equipment is comprisedconsists of the following (in thousands):

 

 

March 31,

  

December 31,

  

September 30,

  

December 31,

 
 

2019

  

2018

  

2019

  

2018

 

Medical Equipment for sale or rental

 $1,810  $1,601  $2,051  $1,601 
                

Medical Equipment in rental service

  65,131   61,429   73,433   61,429 

Medical Equipment in rental service - pump reserve

  (562)  (530)  (644)  (530)

Accumulated depreciation

  (38,460)  (37,411)  (40,520)  (37,411)

Medical Equipment in rental service - net

  26,109   23,488   32,269   23,488 
                

Total

 $27,919  $25,089  $34,320  $25,089 

 

Depreciation expense for medical equipment for the three and nine months ended March 31,September 30, 2019 was $1.7$2.0 million and $5.4 million, respectively, compared to $1.5 million and $4.5 million for the same prior year period,periods, respectively, which were recorded in “cost of revenues” for each period.

 

 

5.5.

Property and Equipment

 

Property and equipment is comprisedconsists of the following (in thousands):

 

 

March 31, 2019

  

December 31, 2018

  

September 30, 2019

  

December 31, 2018

 
 

Gross Assets

  

Accumulated Depreciation

  

Total

  

Gross Assets

  

Accumulated Depreciation

  

Total

  

Gross

Assets

  

Accumulated

Depreciation

  

Total

  

Gross

Assets

  

Accumulated

Depreciation

  

Total

 

Furniture, fixtures, and equipment

 $3,750  $(3,318) $432  $3,717  $(3,257) $460  $4,229  $(3,446) $783  $3,717  $(3,257) $460 

Automobiles

  117   (81)  36   118   (95)  23   117   (87)  30   118   (95)  23 

Leasehold improvements

  2,002   (1,102)  900   2,219   (1,257)  962   3,202   (1,170)  2,032   2,219   (1,257)  962 
                                                

Total

 $5,869  $(4,501) $1,368  $6,054  $(4,609) $1,445  $7,548  $(4,703) $2,845  $6,054  $(4,609) $1,445 

 

Depreciation expense for property and equipment for both the three and nine months ended March 31,September 30, 2019 and 2018 was $0.1 million.million and $0.3 million, respectively, compared to $0.1 million and $0.3 million for the same prior year periods, respectively. This expense was recorded in general and administrative expenses.

 

8

Table of Contents

 

 

6.      Intangible Assets

 

The carrying amount and accumulated amortization of intangible assets is comprised of the following (in thousands):

 

 

March 31, 2019

  

December 31, 2018

  

September 30, 2019

  

December 31, 2018

 
 

Gross Assets

  

Accumulated Amortization

  

Net

  

Gross Assets

  

Accumulated Amortization

  

Net

  

Gross

Assets

  

Accumulated

Amortization

  

Net

  

Gross

Assets

  

Accumulated

Amortization

  

Net

 

Nonamortizable intangible assets:

                        

Nonamortizable intangible assets

                        

Trade names

 $2,000  $-  $2,000  $2,000  $-  $2,000  $2,000  $-  $2,000  $2,000  $-  $2,000 

Amortizable intangible assets:

                                                

Trade names

  23   (23)  -   23   (23)  -   23   (23)  -   23   (23)  - 

Physician and customer relationships

  36,534   (24,769)  11,765   36,534   (24,175)  12,359   36,534   (25,956)  10,578   36,534   (24,175)  12,359 

Non-competition agreements

  1,136   (1,136)  -   1,136   (1,136)  -   1,136   (1,136)  -   1,136   (1,136)  - 

Software

  11,230   (6,255)  4,975   11,230   (5,724)  5,506   11,230   (7,269)  3,961   11,230   (5,724)  5,506 
                                                

Total nonamortizable and amortizable intangible assets

 $50,923  $(32,183) $18,740  $50,923  $(31,058) $19,865  $50,923  $(34,384) $16,539  $50,923  $(31,058) $19,865 

 

Amortization expense for the three and nine months ended March 31,September 30, 2019 was $1.1 million and $3.3 million, respectively, compared to $1.2 million and $3.5 million for the three months ended March 31, 2018.same prior year periods, respectively. Expected annual amortization expense for intangible assets recorded as of March 31,September 30, 2019 is as follows (in thousands):

 

  

4/1-12/31/2019

  

2020

  

2021

  

2022

  

2023

  

2024 and thereafter

  

Total

 
                             

Amortization expense

 $3,277  $4,285  $3,930  $2,051  $548  $2,649  $16,740 
  

10/1 -

                  

2024 and

 
  

12/31/2019

  

2020

  

2021

  

2022

  

2023

  

thereafter

 
                         

Amortization expense

 $1,076  $4,285  $3,930  $2,051  $548  $2,649 

 

7.7.

Debt

On April 15, 2019, the Company sold for $2.0 million and immediately leased back certain medical equipment in rental service to a third party specializing in such transactions. The leaseback term is 36 months. Because the arrangement contains a purchase option that the Company is reasonably certain to exercise, this transaction did not qualify for the sale-leaseback accounting under ASC 842. The medical equipment remains recorded on the accompanying condensed consolidated balance sheet and the proceeds received have been classified as an Other Financing liability, which is being paid off monthly over the term of the lease. The balance of Other Financing as of September 30, 2019 was $1.8 million.

 

On February 5, 2019, the Company and its primary lender entered into the fifth amendment (the “Fifth Amendment”) to its existing credit facility (the “Credit Agreement”). Among other things, the Fifth Amendment amended the Credit Agreement to (1) increase our borrowing capacity under our existing equipment line to $8.0 million, (2) revise the definition of earnings before interest, taxes, depreciation and amortization, a non-GAAP financial measure, to include additional add-back adjustments for the years ended or ending December 31, 2018 and 2019, (3) revise the definition of fixed charge coverage ratio for the year ending December 31, 2019 to include an unfinanced portion of capital expenditures of up to $7.0 million for the year ending December 31, 2019, (4) revise the Credit Agreement’s maximum permitted indebtedness to finance the acquisition, construction or improvement of any fixed or capital assets and (5) revise the maximum leverage ratio for each of the quarters during December 31, 2018 and December 31, 2019.

 

9

As of March 31,September 30, 2019, the Company’s term loans and equipment line under its credit facility had balances of $30.4$27.7 million and $2.6$8.0 million, respectively. The net availability under the revolving credit line under the credit facility is based upon our eligible accounts receivable and eligible inventory and is computed as follows (in thousands):

 

 

March 31,

  

December 31,

  

September 30,

  

December 31,

 
 

2019

  

2018

  

2019

  

2018

 

Revolver:

                

Gross availability

 $10,922  $9,973  $11,000  $9,973 

Outstanding draws

  -   -   -   - 

Letters of credit

  (1,750)  (750)  (1,750)  (750)

Landlord reserves

  (71)  (70)  (71)  (70)

Availability on Revolver

 $9,101  $9,153 

Net availability

 $9,179  $9,153 

 

The Company had future maturities of loans and other financing as of March 31,September 30, 2019 as follows (in thousands):

 

 

2019

  

2020

  

2021

  

2022

  

2023 and thereafter

  

Total

  

2019

  

2020

  

2021

  

2022

  

2023 and

thereafter

  

Total

 

Term Loan A

 $2,688  $3,584  $16,143  $-  $-  $22,415  $896  $3,584  $16,143  $-  $-  $20,623 

Term Loan C

  1,229   1,229   5,528           7,986   307   1,229   5,529   -   -   7,065 

Equipment Line

  128   512   512   512   898   2,562   400   1,600   1,600   1,600   2,800   8,000 

Unamortized value of the debt issuance costs

  (29)  (39)  (39)  -   -   (107)  (10)  (39)  (39)  -   -   (88)

Other financing

  152   652   725   222   -   1,751 

Total

 $4,016  $5,286  $22,144  $512  $898  $32,856  $1,745  $7,026  $23,958  $1,822  $2,800  $37,351 

 

9

Table of Contents

 

The following is a breakdown of the Company’s current and long-term debt as follows (in thousands):

 

March 31, 2019

 

December 31, 2018

 

September 30, 2019

September 30, 2019

 

December 31, 2018

 
                                                  
 

Current Portion

  

Long-Term Portion

  

Total

   

Current Portion

  

Long-Term Portion

  

Total

  

Current

Portion

  

Long-Term

Portion

  

Total

   

Current

Portion

  

Long-Term

Portion

  

Total

 

Term Loan A

 $3,584  $18,831  $22,415 

Term Loan A

 $3,584  $19,727  $23,311  $3,584  $17,039  $20,623 

Term Loan A

 $3,584  $19,727  $23,311 

Term Loan C

  1,536   6,450   7,986 

Term Loan C

  1,229   6,757   7,986   1,229   5,836   7,065 

Term Loan C

  1,229   6,757   7,986 

Equipment Line

  256   2,306   2,562 

Equipment Line

  128   2,434   2,562   1,600   6,400   8,000 

Equipment Line

  128   2,434   2,562 

Unamortized value of debt issuance costs

  (39)  (68)  (107)

Unamortized value of debt issuance costs

  (38)  (76)  (114)  (39)  (49)  (88)

Unamortized value of debt issuance costs

  (38)  (76)  (114)

Other financing

  635   1,116   1,751 

Other financing

  -   -   - 

Total

 $5,337  $27,519  $32,856 

Total

 $4,903  $28,842  $33,745  $7,009  $30,342  $37,351 

Total

 $4,903  $28,842  $33,745 

 

As of March 31,September 30, 2019, interest on the credit facility is payable at our option as a (i) Eurodollar Loan, which bears interest at a per annum rate equal to the applicable 30-day London Interbank Offered Rate (“LIBOR”) plus an applicable margin ranging from 2.00% to 3.00% or (ii) CB Floating Rate (“CBFR”) Loan, which bears interest at a per annum rate equal to the greater of (a) the lender’s prime rate or (b) LIBOR plus 2.50%, in each case, plus a margin ranging from -1.00% to 0.25%. The actual Eurodollar Loan rate at March 31,September 30, 2019 was 5.25%4.81% (LIBOR of 2.50%2.06% plus 2.75%). The actual CBFR Loan rate at March 31,September 30, 2019 was 5.50%5.00% (lender’s prime rate of 5.50%5.00%).

 

As of March 31,September 30, 2019, the Company was in compliance with all debt-related covenants under the Credit Agreement.

 

On November 7, 2019, the Company entered into the Sixth Amendment to the Credit Agreement (the “Sixth Amendment”). See Note 12 to the accompanying unaudited condensed consolidated financial statements for further details on the Sixth Amendment.

 

8.8.

Income Taxes

 

During both the three and nine months ended March 31,September 30, 2019, and 2018, the Company recorded expense provision for income taxes of less than $0.1 million.million and $0.2 million, respectively. The income tax provision relates principally to the Company’s state and local taxes and foreign operations in Canada. During the three and nine months ended September 30, 2018, the Company recorded expense provision for income taxes of less than $0.1 million and $0.1 million, respectively.

10

 

The Company’s realization of its deferred tax assets is dependent upon many factors, including, but not limited to, the Company’s ability to generate sufficient taxable income. Management assesses the available positive and negative evidence to estimate if sufficient future taxable income will be generated to use the existing deferred tax assets. The Company’s management has determined that it is not more likely than not that the Company will not recognize the benefits of its federal and state deferred tax assets. Accordingly, the Company had a full valuation allowance for all deferred tax assets at March 31,September 30, 2019 and December 31, 2018.

10

 

 

9.

Commitments, Contingencies and Litigation

 

From time to time in the ordinary course of its business, the Company may be involved in legal proceedings, the outcomes of which may not be determinable. The results of litigation are inherently unpredictable. Any claims against the Company, whether meritorious or not, could be time consuming, result in costly litigation, require significant amounts of management time and result in diversion of significant resources. The Company is not able to estimate an aggregate amount or range of reasonably possible losses for those legal matters for which losses are not probable and estimable, primarily for the following reasons: (i) many of the relevant legal proceedings are in preliminary stages and, until such proceedings develop further, there is often uncertainty regarding the relevant facts and circumstances at issue and potential liability; and (ii) many of these proceedings involve matters of which the outcomes are inherently difficult to predict. The Company has insurance policies covering potential losses where such coverage is cost effective.effective and available.

 

The Company is not involved in any legal proceedings that the Company currently believes could have a material effect on the Company’s financial condition, results of operations or cash flows.

 

 

10.

(Loss)     Earnings (Loss) Per Share

 

Basic income (loss) income per share is computed by dividing net income (loss) income by the weighted average number of common shares outstanding during the period. Diluted income (loss) income per share assumes the issuance of potentially dilutive shares of common stock during the period. The following table reconciles the numerators and denominators of the basic and diluted income (loss) income per share computations:

 

 

Three Months Ended

 
 

March 31

  

Three Months Ended September 30

  

Nine Months Ended September 30

 

Numerator:

 

2019

  

2018

  

2019

  

2018

  

2019

  

2018

 

Net (loss) income (in thousands)

 $(960) $204 

Net income (loss) (in thousands)

 $1,135  $(519) $556  $(820)

Denominator:

                        

Weighted average common shares outstanding:

                        

Basic

  19,580,049   22,799,221   19,781,527   20,672,688   19,690,737   22,043,213 

Dilutive effect of non-vested awards

  -   57,900   897,904   -   813,196   - 

Diluted

  19,580,049   22,857,121   20,679,431   20,672,688   20,503,933   22,043,213 

Net (loss) income per share:

        

Net income (loss) per share:

                

Basic

 $(0.05) $0.01  $0.06  $(0.03) $0.03  $(0.04)

Diluted

 $(0.05) $0.01  $0.05  $(0.03) $0.03  $(0.04)

 

For the three and nine months ended March 31,September 30, 2019, there were no0.1 million and less than 0.1 million, respectively, of stock options thatwith an exercise price above the current average market value of the Company’s common stock were excluded fromnot included in the calculation because they would have an anti-dilutive effect. For the three and nine months ended March 31,September 30, 2018, 0.3 million of stockall options were anti-dilutive due to the Company’s net losses for those periods and therefore not included in the calculation because they would have an anti-dilutive effect.

calculation.

 

11.11.

Leases

 

On January 1, 2019 (the “Effective Date”), the Company adopted ASU 2016-02, Leases (Topic 842); ASU 2018-10, Codification Improvements to Topic 842, Leases; and ASU 2018-11, Targeted Improvements (collectively, “Topic 842”) using a modified retrospective transition approach, which requires Topic 842 to be applied to all leases existing at the date of initial application. Under Topic 842, lessees are required to recognize a lease liability and right-of-use asset (“ROU asset”) for all leases and to disclose key information about leasing arrangements. Additionally, leases will be classified as either financing or operating; the classification will determine the pattern of expense recognition and classification within the statement of operations. The Company has elected to apply its lease accounting policy only to leases with a term greater than twelve months.

 

11

The Effective Date is the Company’s date of initial application. Consequently, our financial information was not updated and the disclosures required under the new standard are not provided for dates and periods prior to January 1, 2019.

 

Topic 842 provides several optional practical expedients that can be adopted at transition. We have elected the “package of practical expedients”, which does not require us to reassess our prior conclusions regarding lease identification, lease classification and initial direct costs. We did not elect the practical expedient of hindsight to the evaluation of lease options (e.g. renewal).

11

 

The most significant effects related to this adoption relate to (i) the recognition of new ROU assets and lease liabilities on our balance sheet for our real estate and equipment operating leases; and (ii) significant new disclosures about our leasing activities. Upon adoption, we recognized approximately $3.1 million in additional operating lease liabilities with corresponding ROU assets of approximately the same amount.

 

Topic 842 also provides practical expedients for an entity’s ongoing accounting. We have elected the “combining lease and non-lease components” practical expedient and also elected to apply the short-term lease recognition exemption to certain leases; therefore, we did not recognize ROU assets and lease liabilities for these leases.

 

In adopting Topic 842, we have determined and will continue to determine whether an arrangement is a lease at inception. Our operating leases are primarily for office space, service facility centers and equipment under operating lease arrangements that expire at various dates over the next seventen years. Our leases do not contain any restrictive covenants. Our office leases generally contain renewal options for periods ranging from one to five years. Because we are not reasonably certain to exercise these renewal options, the options are not considered in determining the lease term, and payments associated with the option years are excluded from lease payments. Our office leases do not contain any material residual value guarantees. Our equipment leases generally do not contain renewal options. We are not reasonably certain to exercise the renewal options for those equipment leases that do contain renewal options, thus, the options are not considered in determining the lease term and payments associated with the option years are excluded from lease payments.

 

For our equipment leases, we have used and will use the implicit rate in the lease as the discount rate, when available, otherwise, we use our incremental borrowing rate as the discount rate. For our office leases, the implicit rate is typically not available, so we have used and will use our incremental borrowing rate as the discount rate. Our lease agreements include both lease and non-lease components. We have elected the practical expedient that allows us to combine lease and non-lease components for all of our leases.

 

Payments due under our operating leases include fixed payments as well as variable payments. For our office leases, variable payments include amounts for the Company’s proportionate share of operating expenses, utilities, property taxes, insurance, common area maintenance and other facility-related expenses. For our equipment leases, variable payments may consist of sales taxes, property taxes and other fees.

 

The components of lease costs for the three and nine months ended March 31,September 30, 2019 are as follows (in thousands):

 

 

Three Months Ended

 
 

March 31,

  

Three Months Ended

  

Nine Months Ended

 
 

2019

  

September 30, 2019

  

September 30, 2019

 

Operating lease cost

 $387  $533  $1,425 

Variable lease cost

  75   56   182 

Total lease cost

 $462  $589  $1,607 

 

Operating lease expense for the three and nine months ended March 31,September 30, 2018 were $0.3 million.was $0.4 million and $1.1 million, respectively.

12

Table of Contents

 

Amounts reported in the condensed consolidated balance sheet as of March 31,September 30, 2019 for our operating leases are as follows (in thousands):

 

 

March 31, 2019

  

September 30, 2019

 

Operating lease ROU assets

 $2,671  $5,004 
        
Current operating lease liabilities (included in other current liabilities)  1,311  $1,321 

Operating lease liabilities, net of current portion

  1,479   3,944 

Total operating lease liabilities

 $2,790  $5,265 

 

12

Table of Contents

 

Supplemental cash flow information and non-cash activity related to our leases are as follows (in thousands):

 

 

Three Months Ended

 
 

March 31,

  

Nine Months Ended

 
 

2019

  

September 30, 2019

 

Cash paid for amounts included in the measurement of lease liabilities and ROU assets:

        

Operating cash flow from operating leases

 $360  $1,201 
        

ROU assets recognized upon adoption of Topic 842:

    

ROU assets obtained in exchange for lease obligations:

    

Operating leases

  3,060  $3,338 

 

Weighted average remaining lease terms and discount rates for our leases as of March 31,September 30, 2019 are as follows:

 

  

Years

 

Weighted average remaining lease term:

    

Operating leases

  4.07.5 

  

Rate

 

Weighted average discount rate:

    

Operating leases

  6.67.6%

 

Future maturities of lease liabilities as of March 31,September 30, 2019 are as follows (in thousands):

 

   

Operating Leases (a)

 
 

2019

 $1,094 
 

2020

  818 
 

2021

  292 
 

2022

  232 
 

2023

  230 
 

Thereafter

  611 
 

Total undiscounted lease payments

  3,277 
 

Less: Imputed interest

  (487)
 

Total lease liabilities

 $2,790 
      
  

Operating Leases

 

2019

 $398 

2020

  1,328 

2021

  772 

2022

  706 

2023

  719 

Thereafter

  3,506 

Total undiscounted lease payments

  7,429 

Less: Imputed interest

  (2,164)

Total lease liabilities

 $5,265 

(a)Excludes $4.2 million of legally binding minimum lease payments for an office lease signed but not yet commenced. This lease has an expected term of 10 years and is expected to commence later in 2019.

 

The Company disclosed in our 2018 Annual Report on Form 10-K maturities of lease liabilities as of December 31, 2018, in accordance with ASC 840. During the quarter ended March 31, 2019, the Company determined that it improperly included certain lease commitments in the maturities table as of December 31, 2018 in Note 10 of the 2018 Annual Report on Form 10-K. The table overstated our lease maturities as follows (in thousands): $121 in 2019, $370 in 2020, $381 in 2021, $392 in 2022, $404 in 2023 and $2,528 in the thereafter period.

 

13

Table of Contents

The Company assessed the materiality of this error, considering both the qualitative and quantitative factors and determined that for the year ended December 31, 2018, the error was immaterial. The Company has decided to correct this immaterial error as a revision to our previously issued financial statements by adjusting the maturities of the lease liabilities as of December 31, 2018 for the overstated amounts as reflected in the table below (in thousands):

 

      

Operating

     
  

Capital Leases

  

Leases (As Revised)

  

Total (As Revised)

 

2019

 $33  $1,745  $1,778 

2020

  -   1,347   1,347 

2021

  -   726   726 

2022

  -   624   624 

2023

  -   636   636 

Thereafter

  -   3,071   3,071 

Total required payments

 $33  $8,149  $8,182 

Less amounts representing interest (3.5%)

  -         

Present value of minimum lease payments

  33         

Less current maturities

  (33)        

Long-term capital lease liability

 $-         

 

  

Capital

Leases

  

Operating

Leases

(As Revised)

  

Total

(As Revised)

 

2019

 $33  $1,745  $1,778 

2020

  -   1,347   1,347 

2021

  -   726   726 

2022

  -   624   624 

2023

  -   636   636 

Thereafter

  -   3,071   3,071 

Total require payments

 $33  $8,149  $8,182 

Less amounts representing interest (3.5%)

  -         

Present value of minimum lease payments

  33         

Less current maturities

  (33)        

Long-term capital lease liability

 $-         

12.

Subsequent Events

Sixth Amendment to Credit Agreement

On November 7, 2019, the Company entered into the Sixth Amendment to the Credit Agreement. The Sixth Amendment amended the Credit Agreement to, among other things:

provide for a 2019 Capital Expenditure Loan Commitment of $10.0 million (in addition to the existing Capital Expenditure Loan Commitment of $8.0 million), which may be drawn upon until the earlier of the full commitment being advanced or December 31, 2020 (if the same is a Business Day, or if not then the immediately next succeeding Business Day), to be used solely to purchase Eligible Equipment to be used in the Borrowers’ business and in amounts not to exceed 90.0% of the invoiced hard costs of such acquired equipment;

increase the Revolving Commitment to $11.8 million;

revise the definition of EBITDA to include the following additional or revised add-back adjustments: (i) one-time charges in an aggregate amount not to exceed $0.3 million and incurred prior to December 31, 2019 relating to Borrower’s integration of business previously served by another major provider of electronic oncology pumps; (ii) one-time charges in an aggregate amount not to exceed $0.3 million and incurred prior to December 31, 2019 relating to Borrowers’ facility move; (iii) lease buyout expenses not to exceed: (x) $0.1 million incurred on or prior to December 31, 2018; (y) $0.2 million incurred after December 31, 2018 but on or prior to March 31, 2019; and (z) $0.2 million incurred after September 30, 2019 but on or prior to December 31, 2020; and (iv) any other non-cash charges for such period (but excluding (A) any non-cash charge in respect to an item that was included in Net Income in a prior period and (B) any non-cash charge that relates to the write-down or write-off of Inventory, Medical Equipment Held for Sale or Rental and Medical Equipment in Rental Service in excess of $0.5 million in any consecutive twelve month period);

revise the definition of Fixed Charge Coverage Ratio to mean, for any period, the ratio of (a) EBITDA minus Maintenance Capital Expenditures (defined to mean, for any period, 50.0% of depreciation expense) to (b) Fixed Charges, all calculated for the Company and its Subsidiaries on a consolidated basis in accordance with GAAP;

revise the definitions of Revolving Credit Maturity Date and Term Maturity Date to mean the date five years after the Sixth Amendment Effective Date (if the same is a Business Day, or if not then the immediately next succeeding Business Day) and add a definition for the 2019 Capital Expenditure Loan Maturity Date to provide for the same maturity date;

reflect the refinancing of the Term A Loans, Term B Loans and Term C Loan as a single Term Loan on the Sixth Amendment Effective Date and, commencing on the last Business Day of December 2019, the consecutive quarterly principal installment payments will change to approximately $1.2 million. This will change our future maturities of loans and other financing as follows: reduction of $0.1 million for the remainder of 2019, reduction of $0.2 million in 2020, reduction of $20.7 million in 2021, increase of $4.6 million in 2022 and an increase of $12.7 million in the 2023 and thereafter period; and  

 

1314

 

revise Section 5.01(e) of the Credit Agreement, which governs the Borrowers’ Financial Statements delivery to Lender, to provide that Borrowers shall deliver the Financial Statements (x) as soon as possible but in any event within 30 days of the end of each fiscal quarter of the Borrower, or within 30 days of the end of each calendar month if any Revolving Loans were outstanding in month, (y) in connection with, and prior to, requesting any Letter of Credit and (z) at such other times as may be requested by the Lender.

Segment Reporting

The Company is currently evaluating its internal financial reporting and the discrete financial measures utilized by the chief operating decision maker, which we expect to result in reportable segment disclosure for the year ended December 31, 2019 or the first quarter ended March 31, 2020.

15

 

Item 2.     Management’s Discussion and Analysis of Financial Condition and Results of Operations

 

The terms “InfuSystem”, the “Company”, “we”, “our” and “us” used herein refer to InfuSystem Holdings, Inc. and its subsidiaries.

 

Cautionary Statement Regarding Forward-Looking Statements

 

Certain statements contained in this quarterly report on Form 10-Q are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”) and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). The words “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “expect,” “strategy,” “future,” “likely,” variations of such words, and other similar expressions, as they relate to the Company, are intended to identify forward-looking statements. However, the absence of these words or similar expressions does not mean that a statement is not forward-looking. In connection with the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, the Company is identifying certain factors that could cause actual results to differ, perhaps materially, from those indicated by these forward-looking statements. Those factors, risks and uncertainties include, but are not limited to, potential changes in overall healthcare reimbursement, including the Centers for Medicare and Medicaid Services (“CMS”) competitive bidding and fee schedule reductions, sequestration, concentration of customers, increased focus on early detection of cancer, competitive treatments, dependency on Medicare Supplier Number, availability of chemotherapy drugs, global financial conditions, changes and enforcement of state and federal laws, natural forces, competition, dependency on suppliers, risks in acquisitions & joint ventures, U.S. Healthcare Reform, relationships with healthcare professionals and organizations, technological changes related to infusion therapy, the Company’s ability to implement information technology improvements and to respond to technological changes, the ability of the Company to successfully integrate acquired businesses, dependency on key personnel, dependency on banking relations and the ability to comply with our credit facility covenants, and other risks associated with our common stock, as well as any litigation toin which the Company may be involved in from time to time; and other risk factors as discussed in the Company’s annual report on Form 10-K for the year ended December 31, 2018 and in other filings made by the Company from time to time with the Securities and Exchange Commission (“SEC”). Our annual report on Form 10-K is available on the SEC’s EDGAR website at www.sec.gov, and a copy may also be obtained by contacting the Company. All forward-looking statements made in this Form 10-Q speak only as of the date of this report. We do not intend, and do not undertake any obligation, to update any forward-looking statements to reflect future events or circumstances after the date of such statements, except as required by law.

 

Overview

 

We are a leading provider of infusion pumps and related products and services for patients in the home, oncology clinics, ambulatory surgery centers and other sites of care from five locations in the United States and Canada. Through our operating subsidiaries, including InfuSystem, Inc. (“ISI”) and First Biomedical, Inc. (“First Biomedical”), we provide our products and services to hospitals, oncology practices and facilities and other alternate site health care providers. Headquartered in Madison Heights, Michigan, we deliver local, field-based customer support and also operate pump service and repair Centers of Excellence in Michigan, Kansas, California, Massachusetts and Ontario, Canada. ISI is accredited by the Community Health Accreditation Program while First Biomedical is ISO certified.

 

Our core service is to supply electronic ambulatory infusion pumps and associated disposable supply kits to oncology clinics, infusion clinics and hospital outpatient chemotherapy clinics to be utilized in the treatment of a variety of cancers including colorectal cancer and other disease states. Colorectal cancer is the third most prevalent form of cancer in the United States, according to the American Cancer Society, and the standard of care for the treatment of colorectal cancer relies upon continuous chemotherapy infusions delivered via ambulatory infusion pumps.

 

In addition, we sell or rent new and pre-owned pole mounted and ambulatory infusion pumps to, and provide biomedical recertification, maintenance and repair services for, oncology practices as well as other alternate site settings including home care and home infusion providers, skilled nursing facilities, pain centers and others. We also provide these products and services to customers in the small-hospital market.

 

We are currently evaluating our internal financial reporting and the discrete financial measures utilized by the chief operating decision maker, which we expect to result in reportable segment disclosure for the year ended December 31, 2019 or the first quarter ended March 31, 2020.

We purchase new and pre-owned pole mounted and ambulatory infusion pumps from a variety of sources on a non-exclusive basis. We repair, refurbish and provide biomedical certification for the devices as needed. The pumps are then available for sale, rental or to be used within our ambulatory infusion pump management service.

 

Our payor environment is in a constant state of change. Management is intent on extending its considerable breadth of payor contracts as patients move into different insurance coverages, including Medicaid and Insurance Marketplace products. In some cases, this may slightly reduce our aggregate billed revenues payment rate but result in an overall increase in collected revenues, effectively lessening bad debt expense on a micro level, but due to the mix of all payors may not have an impact on overall bad debt expense. Consequently, we are increasingly focused on net revenues, which include a reduction for bad debt.

 

1416

Table of Contents

 

In the midst of changes in the healthcare arena, we believe that we will support our overall business strategy discussed above by (i) focusing on supporting recurring revenues by increasing our pump fleet; (ii) improving liquidity and strengthening ourthe balance sheet by keeping debt levels comparable to our operations; (iii) improving internal operational efficiencies; (iv) increasing our product and services offerings; (v) enhancing our technology offerings to the patients and providers of care; and (vi) investigating synergistic acquisitions.

InfuSystem Holdings, Inc. Results of Operations for the Three Months Ended MarchSeptember 310, 2019 Compared to the Three Months Ended MarchSeptember 310, 2018

 

Net Revenues

 

Our net revenues for the quarter ended March 31,September 30, 2019 were $18.2$21.5 million, an increase of $1.7$4.8 million, or 10.4%28.9%, compared to $16.5$16.7 million for the quarter ended March 31,September 30, 2018. During thethis period, net revenues from rentals increased $0.6$3.5 million, or 4.5%25.5%, compared to the same prior year period. This increase was primarily attributable to growth in the Company’s customer base due to favorable changes in the competitive environment for oncology services and growth in its pain management business as well as decreased allowance for bad debt expense.business. Net revenues from product sales for the three months ended March 31,September 30, 2019 were $3.1$4.2 million, an increase of $1.0$1.3 million, or 51.6%45.0%, compared to the same period of 2018. This increase was primarily the result of an increase in equipment sales of $1.0 million and disposable sales of $0.6 million and equipment sales of $0.4$0.3 million due to the timing of pump sales and the Company’s efforts to expand its product offering and the timing of pump sales.offering.

 

Gross Profit

 

Gross profit for the quarter ended March 31,September 30, 2019 was $10.3$12.2 million, an increase of $0.1$2.6 million, or 1.0%26.5%, compared to the quarter ended March 31,September 30, 2018. As a percentage of revenues, gross profit for the quarter ended March 31,September 30, 2019 was 56.8%57.0%, down from 62.1%58.0% for the same prior year period primarily due to growth in the Company’s lower margin productsproduct sales and increased supply costs in anticipation of future growth. The increase in gross profit for the period iswas mainly due to the increase in net revenues for the period, which was partially offset by an increase of $0.5$0.9 million in the costs of disposablespumps and accessories sold, $0.5$0.4 million in the costs of supply and pump rentals, $0.4 million in pump depreciation expense, $0.3 million in the costs of pumps and accessoriesdisposables sold, and $0.2$0.1 million in pump depreciation expense.service, repair and maintenance costs and $0.1 million in freight costs.

 

Amortization of Intangible Assets

 

Amortization of intangible assets for the quarter ended March 31,September 30, 2019 was $1.1 million, a decrease of $0.1 million compared to the same prior year period. This decrease is attributable to certain intangible assets becoming fully amortized, thus, the related amortization of those projects no longer existed in the firstthird quarter of 2019.

 

Selling and Marketing Expenses

 

Selling and marketing expenses for the quarter ended March 31,September 30, 2019 were $2.6$2.4 million, an increase of $0.3$0.1 million, or 13.1%3.4%, compared to $2.3 million for the quarter ended March 31,September 30, 2018. This increase was largely attributable to an increase in salaries and related expensescommission expense of $0.1$0.2 million, advertising costs of $0.1 million andwhich was partially offset by a decrease in salaries, travel and related expenses of $0.1 million in support of revenue growth.million. Selling and marketing expenses during these periods consisted of sales personnel salaries, commissions and associated fringe benefitbenefits and payroll-related items, marketing, share-based compensation, travel and entertainment and other miscellaneous expenses.

 

General and Administrative Expenses

 

General and Administrative (“G&A”) expenses for the quarter ended March 31,September 30, 2019 were $7.0$7.1 million, an increase of $0.9$0.8 million, or 14.2%12.9%, from $6.2$6.3 million for the quarter ended March 31,September 30, 2018. The increase in G&A expenses versus the comparable prior year period was primarily due to increases in employee compensation related expenses of $0.5$0.7 million and increases of $0.1 million each for outside services expense, rent expense, telephone expense and accounting fees. These increases were partially offset by a decrease in legal fees and strategic alternative costs of $0.2 million, professional fees and outside services of $0.1 million and service and repair costs of $0.1$0.4 million. The increase in employee compensation related expenses was primarily attributable to a $0.3$0.9 million increase in salaries and related expenses, partially offset by a $0.1$0.2 million increasedecrease in stock compensation expense and a $0.1 million net increase in the incentive bonus accrual.expense.

17

Table of Contents

 

Other Income and Expenses

 

During the quarter ended March 31,September 30, 2019, we incurred interest expense of $0.5 million, an increase of $0.1 million, or 46.0%31.9%, compared to the comparable prior year period. This was a net result of the new term debt and equipment financing for capital expenditures that waswere entered into during the second half of 2018 partially offset by paymentsand first half of the previous term debt as well as2019 and higher blended interest rates in 2019 as compared to 2018.

15

Table of Contents

 

Income Taxes

 

During both the three months ended March 31,September 30, 2019 and 2018, the Company recorded expense provision for income taxes of less than $0.1 million. The provision for income taxes relates principally to the Company’s state and local taxes and foreign operations in Canada.

 

The Company’s realization of its deferred tax assets is dependent upon many factors, including, but not limited to, the Company’s ability to generate sufficient taxable income. Management assesses the available positive and negative evidence to estimate if sufficient future taxable income will be generated to use the existing deferred tax assets. Accordingly, at both March 31,September 30, 2019 and December 31, 2018, the Company had a full valuation allowance for all deferred tax assets, as management determined that it is not more likely than not the Company will not recognize the benefits of its federal and state deferred tax assets.

Results of Operations for the Nine Months Ended September 30, 2019Compared to the Nine Months Ended September 30, 2018

Net Revenues

Our net revenues for the nine months ended September 30, 2019 were $59.4 million, an increase of $9.8 million, or 19.8%, compared to $49.6 million for the nine months ended September 30, 2018. During this period, net revenues from rentals increased $6.3 million, or 15.0%, compared to the same prior year period. This increase was primarily attributable to growth in the Company’s customer base due to favorable changes in the competitive environment for oncology services and growth in its pain management business. Net revenues from product sales for the nine months ended September 30, 2019 were $10.8 million, an increase of $3.5 million, or 47.6%, compared to the same period of 2018. This increase was primarily the result of an increase in equipment sales of $2.2 million and disposable sales of $1.3 million due to the timing of pump sales and the Company’s efforts to expand its product offering.

Gross Profit

Gross profit for the nine months ended September 30, 2019 was $33.9 million, an increase of $4.3 million, or 14.7%, compared to the nine months ended September 30, 2018. As a percentage of revenues, gross profit for the nine months ended September 30, 2019 was 57.1%, down from 59.7% for the same prior year period primarily due to growth in the Company’s lower margin product sales and increased supply costs in anticipation of future growth. The increase in gross profit for the period was mainly due to the increase in net revenues for the period, which was partially offset by an increase of $1.9 million in the costs of pumps and accessories sold, $1.3 million in the costs of supply and pump rentals, $1.1 million in the costs of disposables sold, $0.9 million in pump depreciation expense, $0.2 million in service, repair and maintenance costs and $0.1 million in freight costs.

Amortization of Intangible Assets

Amortization of intangible assets for the nine months ended September 30, 2019 was $3.3 million, a decrease of $0.2 million compared to the same prior year period. This decrease is attributable to certain intangible assets becoming fully amortized, thus, the related amortization of those projects no longer existed in the nine months ended September 30, 2019.

Selling and Marketing Expenses

Selling and marketing expenses for the nine months ended September 30, 2019 were $7.5 million, an increase of $0.5 million, or 7.6%, compared to $7.0 million for the nine months ended September 30, 2018. The increase was largely attributable to an increase in commission expense of $0.4 million, advertising costs of $0.1 million and travel and related expenses of $0.1 million in support of revenue growth, partially offset by a $0.1 million decrease in salaries and related expenses. Selling and marketing expenses during these periods consisted of sales personnel salaries, commissions and associated fringe benefits and payroll-related items, marketing, share-based compensation, travel and entertainment and other miscellaneous expenses.

18

Table of Contents

General and Administrative Expenses

G&A expenses for the nine months ended September 30, 2019 were $20.9 million, an increase of $2.1 million, or 11.0%, from $18.8 million for the same prior year period. The increase in G&A expenses versus the comparable prior year period was primarily due to increases in employee compensation related expenses of $1.7 million, outside services of $0.4 million, rent expense of $0.2 million and accounting fees of $0.2 million. These increases were partially offset by a decrease in legal and strategic alternative costs of $0.4 million. The increase in employee compensation related expenses was primarily attributable to a $1.3 million increase in salaries and related expenses, $0.3 million net increase in the incentive bonus accrual and a $0.1 million increase of stock compensation expense.

Other Expenses

During the nine months ended September 30, 2019, we incurred interest expense of $1.4 million, an increase of $0.5 million, or 46.4%, compared to the comparable prior year period. This was a net result of the new term debt and equipment financing for capital expenditures that were entered into during the second half of 2018 and first half of 2019 and higher blended interest rates in 2019 as compared to 2018.

Income Taxes

During the nine months ended September 30, 2019, the Company recorded provision for income taxes of $0.2 million compared to provision for income taxes of $0.1 million for the same comparable prior year period. The provision for income taxes relates principally to the Company’s state and local taxes and foreign operations in Canada.

The Company’s realization of its deferred tax assets is dependent upon many factors, including, but not limited to, the Company’s ability to generate sufficient taxable income. Management assesses the available positive and negative evidence to estimate if sufficient future taxable income will be generated to use the existing deferred tax assets. Accordingly, at both September 30, 2019 and December 31, 2018, the Company had a full valuation allowance for all deferred tax assets, as management determined that it is not more likely than not the Company will recognize the benefits of its federal and state deferred tax assets.

 

Liquidity and Capital Resources

 

Overview:

 

We finance our operations and capital expenditures with internally-generated cash from operations and borrowings under our existing credit agreement (the “Credit Agreement”). or other financing arrangements. As of March 31,September 30, 2019, we had cash and cash equivalents of $1.9$3.2 million and $9.1$9.2 million of availability on our revolving credit facility under the Credit Agreement (the”Revolver”(the “Revolver”) compared to $4.3 million of cash and cash equivalents and $9.2 million of availability on our Revolver at December 31, 2018. Our liquidity and borrowing plans are established to align with our financial and strategic planning processes and ensure we have the necessary funding to meet our operating commitments, which primarily include the purchase of pumps and inventory, and payroll and general expenses. We also take into consideration our overall capital allocation strategy which includes investment for future growth, share repurchases and potential acquisitions. We believe we have adequate sources of liquidity and funding available for at least the next year, however, there are a number of factors that may negatively impact our available sources of funds. The amount of cash generated from operations will be dependent upon factors such as the successful execution of our business plan and general economic conditions.

 

  Long-Term Debt Activities:

On April 15, 2019, the Company sold for $2.0 million and immediately leased back certain medical equipment in rental service to a third party specializing in such transactions. The leaseback term is 36 months. Because the arrangement contains a purchase option that the Company is reasonably certain to exercise, this transaction did not qualify for the sale-leaseback accounting under ASC 842. The medical equipment remains recorded on the accompanying condensed consolidated balance sheet and the proceeds received have been classified as an Other Financing liability, which is being paid off monthly over the term of the lease. The balance of Other Financing as of September 30, 2019 was $1.8 million.

 

On February 5, 2019, the Company and its primary lender entered into the fifth amendment (the “Fifth Amendment”) to the Credit Agreement. Among other things, the Fifth Amendment amended the Credit Agreement to (1) increase our borrowing capacity under our existing equipment line to $8.0 million, (2) revise the definition of earnings before interest, taxes, depreciation and amortization, a non-GAAP financial measure, to include additional add-back adjustments for the years ended or ending December 31, 2018 and 2019, (3) revise the definition of fixed charge coverage ratio for the year ending December 31, 2019 to include an unfinanced portion of capital expenditures of up to $7.0 million for the year ending December 31, 2019, (4) revise the Credit Agreement’s maximum permitted indebtedness to finance the acquisition, construction or improvement of any fixed or capital assets and (5) revise the maximum leverage ratio for each of the quarters during December 31, 2018 and December 31, 2019.

 

19

Table of Contents

As of March 31,September 30, 2019, our term loans and equipment line under the Credit Agreement had balances of $30.4$27.7 million and $2.6$8.0 million, respectively. The net availability under the Revolver is based upon our eligible accounts receivable and eligible inventory and is computed as follows (in thousands):

 

  

March 31,

  

December 31,

 
  

2019

  

2018

 

Revolver:

        

Gross availability

 $10,922  $9,973 

Outstanding draws

  -   - 

Letters of credit

  (1,750)  (750)

Landlord reserves

  (71)  (70)

Availability on Revolver

 $9,101  $9,153 

16

Table of Contents
  

September 30,

  

December 31,

 
  

2019

  

2018

 

Revolver:

        

Gross availability

 $11,000  $9,973 

Outstanding draws

  -   - 

Letters of credit

  (1,750)  (750)

Landlord reserves

  (71)  (70)

Net availability

 $9,179  $9,153 

 

As of March 31,September 30, 2019, interest on the credit facility is payable at our option as a (i) Eurodollar Loan, which bears interest at a per annum rate equal to the applicable 30-day London Interbank Offered Rate (“LIBOR”) plus an applicable margin ranging from 2.00% to 3.00% or (ii) CB Floating Rate (“CBFR”) Loan, which bears interest at a per annum rate equal to the greater of (a) the lender’s prime rate or (b) LIBOR plus 2.50%, in each case, plus a margin ranging from -1.00% to 0.25%. The actual Eurodollar Loan rate at March 31,September 30, 2019 was 5.25%4.81% (LIBOR of 2.50%2.06% plus 2.75%). The actual CBFR Loan rate at March 31,September 30, 2019 was 5.50%5.00% (lender’s prime rate of 5.50%5.00%).

 

As of March 31,September 30, 2019, the Company was in compliance with all debt-related covenants under the Credit Agreement.

 

On November 7, 2019, the Company and its primary lender entered into the Sixth Amendment to the Credit Agreement. Among other things, the Sixth Amendment amended the Credit Agreement to (1) provide for a new equipment line of $10.0 million in addition to our existing equipment line of $8.0 million, (2) increase the commitment under the Revolver to $11.8 million, (3) revise certain definitions, (4) refinance outstanding term loans into a single term loan and (5) revise the Company’s financial statement delivery requirements. See Note 12, Subsequent Events, to the accompanying unaudited condensed consolidated financial statements for further details regarding the Sixth Amendment to the Credit Agreement.

Share Repurchase Program

On September 30, 2019, our Board of Directors approved a stock repurchase program (the “Share Repurchase Program”) authorizing the Company to repurchase up to $5.0 million of the Company’s outstanding common stock through 2020. The repurchase program will be subject to market conditions, the periodic capital needs of the Company’s operating activities, and the continued satisfaction of all covenants under the Company’s existing Credit Agreement. As of September 30, 2019, we had availability of $9.2 million on our Revolver, all of which could be used to fund stock repurchases, subject to the restrictions and limitations of our Credit Agreement. Repurchases under the program may take place in the open market or in privately negotiated transactions and may be made under a Rule 10b5-1 plan. The repurchase program does not obligate the Company to repurchase shares and may be suspended, terminated, or modified at any time.

As of September 30, 2019, the Company has not repurchased any shares under the Share Repurchase Program.

Cash Flows:

        Operating Cash Flow. Net cash provided by operating activities for the threenine months ended March 31,September 30, 2019 was $1.3$9.5 million compared to net cash provided by operating activities of $1.1$8.2 million for the threenine months ended March 31,September 30, 2018. This increase was primarily attributable to the favorable change in net income (loss) adjusted for non-cash items and the positive cash flow effect of improved working capital, increaseda net incremental increase in accounts payable and other liabilities, which was partially offset by increasedan incremental increase in accounts receivable and other assets, and the cash flow effect from net income in the first quarter of 2018 to a net loss in the first quarter of 2019.receivable.

 

        Investing Cash Flow. Net cash used in investing activities was $2.8$14.2 million for the threenine months ended March 31,September 30, 2019 compared to net cash used in investing activities of $0.2$2.2 million for the threenine months ended March 31,September 30, 2018. The increase in net cash used was due to a $2.4$11.9 million increase in cash used to purchase medical equipment which was partially offset byand other assets and a $0.2$0.1 million decrease in proceeds from the sales of medical equipment.

 

20

Table of Contents

        Financing Cash Flow. Net cash provided by financing activities for the nine months ended September 30, 2019 was $3.5 million compared to net cash used in financing activities for the three months ended March 31, 2019 was $0.9 million compared to cash used of $2.8$5.6 million for the threenine months ended March 31,September 30, 2018. The decreasenet increase in net cash usedprovided was primarily attributable to cash proceeds from our equipment line and proceeds received as part of a new financing arrangement in 2019 and our decision to pay down our term loan debt make required capital lease payments and repurchase shares of common stock as part of a share repurchase program in the first quarter of 2018.

 

Critical Accounting Policies and Estimates

 

The unaudited condensed consolidated financial statements are prepared in conformity with U.S. GAAP, which require the use of estimates, judgments and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses in the periods presented. We believe that the accounting estimates employed are appropriate and resulting balances are reasonable; however, due to inherent uncertainties in making estimates, actual results could differ from the original estimates, requiring adjustments to these balances in future periods. The critical accounting estimates that affect the unaudited condensed consolidated financial statements and the judgments and assumptions used are consistent with those described in the notes to the audited consolidated financial statements in our annual report on Form 10-K for the year ended December 31, 2018, with the exception of our adoption of Topic 842. See Note 11 to the accompanying unaudited condensed consolidated financial statements for further details regarding our adoption of Topic 842.

Item 3.

Quantitative and Qualitative Disclosures About Market Risk

 

We areItem 3.     Quantitative and Qualitative Disclosures About Market Risk

InfuSystem is a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and areis not required to provide the information required under this item.

 

 

Item 4.

Controls and Procedures

 

Evaluation of Disclosure Controls and Procedures and Changes in Internal Control over Financial Reporting

 

We maintain a set of disclosure controls and procedures designed to ensure that material information required to be disclosed in our filings under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms and that material information is accumulated and communicated to our management, including our Chief Executive Officer (“CEO”) and Chief Financial Officer (“CFO”), as appropriate, to allow timely decisions regarding required disclosures. Our CEO and CFO have evaluated these disclosure controls and procedures as of the end of the period covered by this quarterly report on Form 10-Q and have determined that such disclosure controls and procedures were effective.

 

There has been no change in our internal control over financial reporting during our most recent calendar quarter that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

 

17

Table of Contents

 

PART II—OTHER INFORMATION

 

Item 1. Legal Proceedings

 

From time to time in the ordinary course of our business, we may be involved in legal proceedings, the outcomes of which may not be determinable. The results of litigation are inherently unpredictable. Any claims against us, whether meritorious or not, could be time consuming, result in costly litigation, require significant amounts of management time and result in diversion of significant resources. We are not able to estimate an aggregate amount or range of reasonably possible losses for those legal matters for which losses are not probable and estimable, primarily for the following reasons: (i) many of the relevant legal proceedings are in preliminary stages and until such proceedings develop further, there is often uncertainty regarding the relevant facts and circumstances at issue and potential liability; and (ii) many of these proceedings involve matters of which the outcomes are inherently difficult to predict. We have insurance policies covering potential losses where such coverage is cost effective.effective and available.

 

We are not involved in any legal proceedings that we currently believe could have a material effect on our business, financial condition, results of operations or cash flows.

21

Table of Contents

 

Item 1A. Risk Factors

 

For information regarding factors that could affect our results of operations, financial condition and liquidity, refer to the section entitled “Risk Factors” in Part I, Item 1A in our Annual Report on Form 10-K for the year ended December 31, 2018.

 

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

None.

 

Item 3. Defaults Upon Senior Securities

None.

 

Item 4. Mine Safety Disclosures

Not applicable.

 

Item 5. Other Information

None.

 

1822

Table of Contents

 

Item 6.     Exhibits

 

Exhibits 

Exhibits

  

3.1

Amended and Restated Certificate of Incorporation, as amended (incorporated by reference to Exhibit 3.1 to the Company’s current reportCurrent Report on Form 8-K (File No. 1-35020) filed on May 12, 2014)

  

3.2

Amended and Restated By-Laws (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K (File No. 1-35020) filed on July 9, 2018)

10.1

Sixth Amendment to the Credit Agreement, dated as of November 7, 2019, among InfuSystem Holdings, Inc. and Its direct and indirect subsidiaries with JPMorgan Chase Bank, N.A. as Lender (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K (File No. 1-35020) filed on November 12, 2019)

  

31.1*

Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

  

31.2*

Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

  

32.1*

Certification of the Chief Executive Officer pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

  

32.2*

Certification of the Chief Financial Officer pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

101.INS*

XBRL Instance Document

  

101.SCH*

XBRL Taxonomy Extension Schema Document

  

101.CAL*

XBRL Taxonomy Extension Calculation Linkbase Document

  

101.DEF*

XBRL Taxonomy Extension Definition Linkbase Document

  

101.LAB*

XBRL Taxonomy Extension Label Linkbase Document

  

101.PRE*

 

*

XBRL Taxonomy Extension Presentation Linkbase Document

 

Filed herewith

 

1923

Table of Contents

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

 

INFUSYSTEM HOLDINGS, INC.

 

 

 

 

 

 

 

 

 

Date: May 15,November 14, 2019

 

/s/ Richard DiIorio

 

 

 

Richard DiIorio

 

 

 

Chief Executive Officer, President and Director

(Principal Executive Officer)

 

Date: November 14, 2019

(Principal Executive Officer)

/s/ Gregory Schulte

Gregory Schulte

Date: May 15, 2019/s/ Gregory Schulte
Gregory Schulte

Chief Financial Officer

(Principal Accounting and Financial Officer)

 

2024